Kumar Nitish, Kumar Bimlesh, Ashique Sumel, Yasmin Sabina, Venkatesan Kumar, Islam Anas, Ghosh Suman, Sahu Anwesha, Bhui Utpal, Ansari Mohammad Yousuf
SRM Modinagar College of Pharmacy, SRM Institute of Science and Technology (Deemed to be University), Delhi-NCR Campus, Modinagar, Ghaziabad, Uttar Pradesh 201204, India.
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab 144411, India.
Diabetes Res Clin Pract. 2025 Mar;221:112050. doi: 10.1016/j.diabres.2025.112050. Epub 2025 Feb 16.
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) were originally formulated to reduce blood glucose levels in individuals with diabetes. Recent clinical trials indicate that this compound can be repurposed for other critical conditions. A literature search was performed on PubMed, Scopus, Embase, ProQuest, and Google Scholar, utilizing key terms such as SGLT2i, diabetes, and oxidative stress. SGLT2i has significant beneficial effects not only in cardiovascular disease but also in renal dysfunction. SGLT2i therapy can mitigate critical cardiovascular complications like heart attacks, strokes, mortality rates, and hospitalization duration, as well as delay the necessity for dialysis irrespective of diabetic condition. Evidence supports potential advantages of SGLT2 inhibitors for individuals with renal problems and heart failure, regardless of diabetes status. In addition to diabetic mellitus, this analysis explores the latest updates on SGLT2i and the therapeutic advantages it offers in many renal and cardiovascular diseases (CVDs).
钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）最初是为降低糖尿病患者的血糖水平而研制的。最近的临床试验表明，这种化合物可用于其他关键病症。利用SGLT2i、糖尿病和氧化应激等关键词在PubMed、Scopus、Embase、ProQuest和谷歌学术上进行了文献检索。SGLT2i不仅对心血管疾病有显著益处，对肾功能障碍也有显著益处。SGLT2i治疗可减轻心脏病发作、中风、死亡率和住院时间等关键心血管并发症，还可推迟透析必要性，无论糖尿病病情如何。有证据支持SGLT2抑制剂对有肾脏问题和心力衰竭的个体具有潜在优势，无论糖尿病状态如何。除了糖尿病，本分析还探讨了SGLT2i的最新进展及其在许多肾脏和心血管疾病（CVD）中提供的治疗优势。
